Loading...
XSHE
002653
Market cap6.98bUSD
Jun 03, Last price  
44.79CNY
1D
-2.18%
1Q
35.89%
Jan 2017
217.41%
IPO
745.52%
Name

Haisco Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
P/E
169.97
P/S
14.95
EPS
0.26
Div Yield, %
0.77%
Shrs. gr., 5y
0.72%
Rev. gr., 5y
-0.42%
Revenues
3.36b
+11.27%
358,762,468484,571,191581,585,122604,429,653802,069,348992,337,3021,210,595,3831,212,453,3431,435,606,5861,856,160,9253,426,664,2593,937,340,4623,329,599,5742,773,314,8843,015,294,3393,355,070,108
Net income
295m
-24.65%
195,086,739283,719,337305,752,954312,296,110443,060,913519,218,912450,541,060372,157,949452,723,897237,553,210333,228,517493,891,812636,621,367517,582,477391,644,290295,111,611
CFO
450m
+375.51%
94,445,426368,213,627367,380,976260,794,014464,751,585568,414,763502,568,128443,027,933426,111,876391,810,909472,607,295764,259,511206,207,63635,801,45994,546,036449,578,350
Dividend
Sep 18, 20240.145 CNY/sh

Profile

Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers small-volume injections, freeze-dried powder injections, powder injections, large-volume injections, active pharmaceutical ingredient, etc. for various therapeutic fields, including anti-infective, digestive system, blood system, nervous system, parenteral nutrition, antibiotics, first aid, anesthetics, and tumor; and tablets, capsules, granules, and ointments in the fields of cardiovascular, anti-infection, digestive system, CNS system, diabetes, and hepatic diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.
URL
http://www.haisco.com/
IPO date
Jan 17, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,355,070
11.27%
3,015,294
8.73%
Cost of revenue
2,269,245
2,579,421
Unusual Expense (Income)
NOPBT
1,085,825
435,874
NOPBT Margin
32.36%
14.46%
Operating Taxes
6,960
Tax Rate
0.64%
NOPAT
1,078,866
435,874
Net income
295,112
-24.65%
391,644
-24.33%
Dividends
(199,187)
Dividend yield
0.83%
Proceeds from repurchase of equity
(8,162)
(1)
BB yield
0.03%
0.00%
Debt
Debt current
954,431
786,734
Long-term debt
876,376
1,320,494
Deferred revenue
108,473
98,520
Other long-term liabilities
108,852
8,706
Net debt
18,658
706,503
Cash flow
Cash from operating activities
449,578
94,546
CAPEX
(391,009)
Cash from investing activities
(383,190)
Cash from financing activities
328,066
624,230
FCF
947,539
163,504
Balance
Cash
1,328,767
775,390
Long term investments
483,381
625,335
Excess cash
1,644,395
1,249,960
Stockholders' equity
3,341,126
3,071,733
Invested Capital
4,454,956
4,045,560
ROIC
25.38%
11.96%
ROCE
17.79%
8.23%
EV
Common stock shares outstanding
1,114,118
1,075,607
Price
23.15
4.04%
22.25
10.34%
Market cap
25,791,831
7.77%
23,932,266
10.23%
EV
25,801,134
24,736,450
EBITDA
1,305,409
619,997
EV/EBITDA
19.76
39.90
Interest
42,279
50,912
Interest/NOPBT
3.89%
11.68%